Use with caution in diabetes mellitus, hypertension, hypothyroidism, electrolyte abnormalities, sodium and water retention, infections, immunizations, ocular herpes simplex, myasthenia gravis, peptic ulcer disease, psychosis, renal insufficiency. Prolonged corticosteroid use may result in elevated intraocular pressure, glaucoma, or cataracts and has been associated with development of Kaposi sarcoma
Lactation: Unknown whether drug is excreted in milk; use with caution
Indication
Primary and secondary adrenocortical insufficiency in Addison disease, Salt-Losing Forms of Congenital Adrenogenital Syndrome
Acne, hypertension, sodium and water retention, potassium loss, dizziness, itching, skin rash, headache, convulsions, CHF, muscle weakness, hyperglycaemia, HPA and growth suppression, peptic ulcer, cataracts, raised intraocular pressure and reduced visual acuity. Insomnia, Menstrual irregularity, Myopathy, Neuritis, Osteoporosis
Pregnancy Category
Name :
C
Description
Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks
Mode of Action
Potent mineralocorticoid with high glucocorticoid activity; Fludrocortisone promotes increased reabsorption of sodium and excretion of potassium from renal distal tubules
Interaction
May decrease salicylate levels. Anticholinesterase effects are antagonised. Decreased effects with rifampin, barbiturates, hydantoins and phenytoin. Oral contraceptives or ritonavir may increase the plasma concentrations of fludrocortisone. Increased potassium loss with potassium-depleting drugs e.g. thiazides, furosemide or amphotericin B. Increased risk of GI bleeding or ulceration with NSAIDs. May alter efficacy of anticoagulants when used concurrently.
Pregnancy Category Note
Pregnancy category: C
Lactation: Unknown whether drug is excreted in milk; use with caution
Adult Dose
Oral
Adult:
Primary adrenocortical insufficiency
Adrenocortical Insufficiency/Addison Disease
Primary and secondary adrenocortical insufficiency in Addison disease
Usual, 0.1 mg/day PO; range, 0.1 mg PO 3 times weekly to 0.2 mg/day PO
If hypertension occurs: 0.05 mg/day PO
Salt-Losing Forms of Congenital Adrenogenital Syndrome
0.1-0.2 mg/day PO
Child Dose
Not FDA-approved for use in children
Renal Dose
N/A
Administration
N/A
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.